Gut microbiome of helminth-infected indigenous Malaysians is context dependent
- PMID: 36476263
- PMCID: PMC9727879
- DOI: 10.1186/s40168-022-01385-x
Gut microbiome of helminth-infected indigenous Malaysians is context dependent
Abstract
Background: While microbiomes in industrialized societies are well characterized, indigenous populations with traditional lifestyles have microbiomes that are more akin to those of ancient humans. However, metagenomic data in these populations remains scarce, and the association with soil-transmitted helminth infection status is unclear. Here, we sequenced 650 metagenomes of indigenous Malaysians from five villages with different prevalence of helminth infections.
Results: Individuals from villages with higher prevalences of helminth infections have more unmapped reads and greater microbial diversity. Microbial community diversity and composition were most strongly associated with different villages and the effects of helminth infection status on the microbiome varies by village. Longitudinal changes in the microbiome in response to albendazole anthelmintic treatment were observed in both helminth infected and uninfected individuals. Inference of bacterial population replication rates from origin of replication analysis identified specific replicating taxa associated with helminth infection.
Conclusions: Our results indicate that helminth effects on the microbiota were highly dependent on context, and effects of albendazole on the microbiota can be confounding for the interpretation of deworming studies. Furthermore, a substantial quantity of the microbiome remains unannotated, and this large dataset from an indigenous population associated with helminth infections is a valuable resource for future studies. Video Abstract.
Keywords: Albendazole; Helminth; Indigenous population; Metagenomic sequencing; Microbiome.
© 2022. The Author(s).
Conflict of interest statement
Ken Cadwell has received research support from Pfizer, Takeda, Pacific Biosciences, Genentech, and Abbvie. Ken Cadwell was consulted for or has received honoraria from Puretech Health, Genentech, and Abbvie. Ken Cadwell holds US patent 10,722,600 and provisional patents 62/935,035 and 63/157,225. The other authors declare that they have no competing interests.
Figures
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
